The potential value of serum GP73 in the ancillary diagnosis and grading of liver cirrhosis

References

• Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet. 2014; 17383(9930):1749–1761.
   PubMed Web of Science ®Google Scholar
• Bedossa P. Liver biopsy. Gastroenterol Clin Biol. 2008;32(6 Suppl 1):4–7.
   PubMedGoogle Scholar
• Friedrich-Rust M, Ong MF, Martens S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology. 2008;134(4):960–974.
   PubMed Web of Science ®Google Scholar
• Zhu X, Wang LC, Chen EQ, et al. Prospective evaluation of FibroScan for the diagnosis of hepatic fibrosis compared with liver biopsy/AST platelet ratio index and FIB-4 in patients with chronic HBV infection. Dig Dis Sci. 2011;56(9):2742–2749.
   PubMed Web of Science ®Google Scholar
• Lurie Y, Webb M, Cytter-Kuint R, et al. Non-invasive diagnosis of liver fibrosis and cirrhosis. World J Gastroenterol. 2015;21(41):11567–11583.
   PubMed Web of Science ®Google Scholar
• Manning DS, Afdhal NH. Diagnosis and quantitation of fibrosis. Gastroenterology. 2008;134(6):1670–1681.
   PubMed Web of Science ®Google Scholar
• Aubé C, Winkfield B, Oberti F, et al. New Doppler ultrasound signs improve the non-invasive diagnosis of cirrhosis or severe liver fibrosis. Eur J Gastroenterol Hepatol. 2004;16(8):743–751.
   PubMed Web of Science ®Google Scholar
• Aubé C, Oberti F, Korali N, et al. Ultrasonographic diagnosis of hepatic fibrosis or cirrhosis. J Hepatol. 1999;30(3):472–478.
   PubMed Web of Science ®Google Scholar
• Lu FM, Zhang Y. [Diagnostic application of serum GP73 and the relevant mechanism in the diagnosis of liver cirrhosis.]. Zhonghua Gan Zang Bing Za Zhi. 2018;26(5):321–324.
   PubMedGoogle Scholar
• Gatselis NK, Tornai T, Shums Z, et al. Golgi protein-73: a biomarker for assessing cirrhosis and prognosis of liver disease patients. World J Gastroenterol. 2020;1426(34):5130–5145.
   PubMed Web of Science ®Google Scholar
• Qiao Y, Chen J, Li X, et al. Serum gp73 is also a biomarker for diagnosing cirrhosis in population with chronic HBV infection. Clin Biochem. 2014;47(16–17):216–222.
   PubMed Web of Science ®Google Scholar
• Marrero JA, Romano PR, Nikolaeva O, et al. GP73, a resident golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol. 2005;43(6):1007–1012.
   PubMed Web of Science ®Google Scholar
• Gatselis NK, Zachou K, Giannoulis G, et al. Serum cartilage oligomeric matrix protein and golgi protein-73: new diagnostic and predictive tools for liver fibrosis and hepatocellular cancer? Cancers. 2021;13(14):3510. 13
   PubMed Web of Science ®Google Scholar
• Wei H, Li B, Zhang R, et al. Serum GP73, a marker for evaluating progression in patients with chronic HBV infections. PLoS One. 2013;8(2):e53862.
   PubMed Web of Science ®Google Scholar
• Xu XY, Ding HG, Li WG, et al. Chinese guidelines on the management of liver cirrhosis (abbreviated version). World J Gastroenterol. 2020;26(45):7088–7103.
   PubMed Web of Science ®Google Scholar
• Anthony PP, Ishak KG, Nayak NC, et al. The morphology of cirrhosis: definition, nomenclature, and classification. Bull World Health Organ. 1977;55(4):521–540.
   PubMed Web of Science ®Google Scholar
• Xia Y, Zhang Y, Shen M, et al. Golgi protein 73 and its diagnostic value in liver diseases. Cell Prolif. 2019;52(2):e12538.
   PubMed Web of Science ®Google Scholar
• Kladney RD, Cui X, Bulla GA, et al. Expression of GP73, a resident Golgi membrane protein, in viral and nonviral liver disease. Hepatology. 2002;35(6):1431–1440.
   PubMed Web of Science ®Google Scholar
• Ba MC, Long H, Tang YQ, et al. GP73 expression and its significance in the diagnosis of hepatocellular carcinoma: a review. Int J Clin Exp Pathol. 2012;5(9):874–881.
   PubMed Web of Science ®Google Scholar
• Iftikhar R, Kladney RD, Havlioglu N, et al. Disease- and cell-specific expression of GP73 in human liver disease. Am J Gastroenterol. 2004;99(6):1087–1095.
   PubMed Web of Science ®Google Scholar
• Maitra A, Thuluvath PJ. GP73 and liver disease: a (golgi) complex enigma. Am J Gastroenterol. 2004;99(6):1096–1098.
   PubMed Web of Science ®Google Scholar
• Agrawal S, Dhiman RK, Limdi JK. Evaluation of abnormal liver function tests. Postgrad Med J. 2016;92(1086):223–234.
   PubMed Web of Science ®Google Scholar
• Lu LG, [Consensus on the diagnosis and treatment of cholestasis liver diseases]. Zhonghua Gan Zang Bing Za Zhi. 2015;23(12):924–933.
   PubMedGoogle Scholar
• Renou C, Muller P, Jouve E, et al. Revelance of moderate isolated thrombopenia as a strong predictive marker of cirrhosis in patients with chronic hepatitis C virus. Am J Gastroenterol. 2001;96(5):1657–1659.
   PubMed Web of Science ®Google Scholar
• Mao Y, Yang H, Xu H, et al. Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. Gut. 2010;59(12):1687–1693.
   PubMed Web of Science ®Google Scholar
• Witjes CD, van Aalten SM, Steyerberg EW, et al. Recently introduced biomarkers for screening of hepatocellular carcinoma: a systematic review and meta-analysis. Hepatol Int. 2013;7(1):59–64.
   PubMed Web of Science ®Google Scholar
• Li X, Wu K, Fan D. Serum golgi phosphoprotein 2 level: a better marker than alpha-fetoprotein for diagnosing early hepatocellular carcinoma. Hepatology. 2009;50(1):325–325.
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Imamura H, Matsuyama Y, et al. AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. J Gastroenterol. 2010;45(12):1272–1282.
   PubMed Web of Science ®Google Scholar
• Tian L, Wang Y, Xu D, et al. Serological AFP/golgi protein 73 could be a new diagnostic parameter of hepatic diseases. Int J Cancer. 2011;129(8):1923–1931. 15
   PubMed Web of Science ®Google Scholar
• Liu T, Yao M, Liu S, et al. Serum golgi protein 73 is not a suitable diagnostic marker for hepatocellular carcinoma. Oncotarget. 2017;8(10):16498–16506.
   PubMedGoogle Scholar
• Lu FM, Zhang Y. [Diagnostic application of serum GP73 and the relevant mechanism in the diagnosis of liver cirrhosis]. Zhonghua Gan Zang Bing Za Zhi. 2018;26(5):321–324. Chinese
   Google Scholar
• Yao M, Wang L, Leung PSC, Li Y, Liu S, Wang L, Guo X, Zhou G, Yan Y, Guan G, Chen X, Bowlus CL, Liu T, Jia J, Gershwin ME, Ma X, Zhao J, Lu F. The clinical significance of GP73 in immunologically mediated chronic liver diseases: Experimental data and literature review. Clin Rev Allergy Immunol. 2018;54(2):282–294.
   Google Scholar
• Liu L, Wang J, Feng J, et al. Serum golgi protein 73 is a marker comparable to APRI for diagnosing significant fibrosis in children with liver disease. Sci Rep. 2018;8(1):16730.
   PubMedGoogle Scholar
• Wei XF, Shi M, Chen ZR, et al. Expression of GP73 in liver cirrhosis and its assistant value in grading of liver cirrhosis. Chin J Nuclear Med Mol Imag. 2019;39(10):597–600.
   Google Scholar
• Yao M, Wang L, Leung PSC, et al. The clinical significance of GP73 in immunologically mediated chronic liver diseases: experimental data and literature review. Clin Rev Allergy Immunol. 2018;54(2):282–294.
   PubMed Web of Science ®Google Scholar
• Li B, Li B, Guo T, et al. Artificial neural network models for early diagnosis of hepatocellular carcinoma using serum levels of α-fetoprotein, α-fetoprotein-L3, des-γ-carboxy prothrombin, and golgi protein 73. Oncotarget. 2017;8(46):80521–80530.
   PubMedGoogle Scholar
• Xu Z, Liu L, Pan X, et al. Serum golgi protein 73 (GP73) is a diagnostic and prognostic marker of chronic HBV liver disease. Medicine. 2015;94(12):e659.
   PubMed Web of Science ®Google Scholar